Last reviewed · How we verify
Ciprofloxacin 0.3% ophthalmic solution
Ciprofloxacin 0.3% ophthalmic solution works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication and transcription.
Ciprofloxacin 0.3% ophthalmic solution works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication and transcription. Used for Treatment of bacterial conjunctivitis.
At a glance
| Generic name | Ciprofloxacin 0.3% ophthalmic solution |
|---|---|
| Also known as | Ciloxan® |
| Sponsor | Allergan |
| Drug class | fluoroquinolone antibiotic |
| Target | DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
This inhibition prevents bacterial DNA replication and transcription, ultimately leading to bacterial cell death. Ciprofloxacin is a fluoroquinolone antibiotic that targets a wide range of bacteria, including those that cause conjunctivitis and other eye infections.
Approved indications
- Treatment of bacterial conjunctivitis
Common side effects
- Dry eye
- Eye irritation
- Headache
- Dizziness
- Nausea
Key clinical trials
- Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects (PHASE1)
- Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics (NA)
- Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis (PHASE2)
- Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa (PHASE1, PHASE2)
- Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers (PHASE2)
- Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprofloxacin 0.3% ophthalmic solution CI brief — competitive landscape report
- Ciprofloxacin 0.3% ophthalmic solution updates RSS · CI watch RSS
- Allergan portfolio CI